BSX

Boston Scientific (BSX) declined 2.35% on October 21, 2026, underperforming the broader market gains. The stock is rated Zacks Rank #4 (Sell) with a recent downward revision of 0.89% in EPS estimates.

The company is scheduled to report Q3 earnings on October 28, 2026, with projected EPS of $0.76 and revenue of $5.17 billion. While BSX trades at a discount to its industry average P/E ratio, the Medical-Products industry ranks in the bottom 36% of all industries.

Boston Scientific is expected to report Q3 2026 earnings on October 28 with consensus EPS of $0.76 (+1.3% YoY) and revenues of $5.17B (+2.1% YoY). However, the company carries a negative Earnings ESP of -3.63% and a Zacks Rank #4, making it unlikely to beat consensus estimates. While the company has beaten estimates in 3 of the last 4 quarters, recent analyst revisions have turned bearish.

Boston Scientific (BSX) closed at $44.14, up 2.65% on the day but down 2.07% over the past month. The company is expected to report earnings on October 28, 2026, with projected EPS of $0.76 and revenue of $5.17 billion. Despite trading at a Forward P/E discount of 13.28 compared to its industry average of 19.61, BSX carries a Zacks Rank #4 (Sell) rating due to a 1.49% downward revision in consensus EPS projections over the past 30 days.

Boston Scientific (BSX) closed at $42.73, up 1.64% on the day, outperforming the S&P 500. The company is expected to report earnings on October 28, 2026, with predicted EPS of $0.76 (+1.33% YoY) and revenue of $5.17 billion (+2.12% YoY).

However, BSX holds a Zacks Rank #4 (Sell) rating due to a 1.3% decline in consensus EPS estimates over the past month. The stock trades at a Forward P/E of 12.92, below its industry average, but faces headwinds despite valuation appeal.

Boston Scientific (BSX) gained 1.11% on October 8, 2026, outperforming the broader market decline. The medical device manufacturer is expected to report Q3 earnings on October 28 with forecasted EPS of $0.76 (+1.33% YoY) and revenue of $5.17 billion (+2.12% YoY).

However, the stock has declined 7.52% over the past month and holds a Zacks Rank of #4 (Sell) following a 1.3% decrease in consensus EPS estimates over the last 30 days. The stock trades at a Forward P/E of 12.78, below its industry average of 19.24.

Boston Scientific (BSX) has attracted investor attention but faces near-term headwinds. The stock declined 7.5% over the past month, underperforming the S&P 500's +1.4% gain.

While the company demonstrated strong recent earnings and revenue surprises, earnings estimate revisions have been negative over the past month. The stock received a Zacks Rank #4 (Sell) rating, suggesting potential underperformance in the near term, though it trades at a valuation discount to peers.

Boston Scientific (BSX) declined 1.46% to $42.60, underperforming the broader market which gained 0.73%. The stock has lost 7.92% over the past month.

While analysts expect modest earnings growth of 1.33% YoY and revenue growth of 3.25% for the upcoming quarter, the company received a Zacks Rank #4 (Sell) rating due to a 1.3% downward revision in consensus EPS estimates over the last 30 days. However, the stock trades at a discount with a Forward P/E of 13.28 versus the industry average of 19.67.

Boston Scientific's MedSurg segment showed mixed Q2 2026 results with Endoscopy growing 7% and Neuromodulation up 12%, but Urology disappointed with only 1% growth due to sacral neuromodulation recovery delays and stone management portfolio gaps. The company expects flat to low-single digit Urology growth for full-year 2026 but remains confident in 2027 improvement with planned product launches. BSX stock has underperformed the industry and carries a Zacks Rank #4 (Sell) rating.

Johnson & Johnson's shares fell 5.8% after Q3 2026 results showed earnings beat but sales missed expectations. MedTech segment underperformed with only 2.5% growth due to Abiomed declines and international market challenges, while Innovative Medicine remained strong. Despite headwinds, J&J raised full-year guidance and targets over $100 billion in 2026 revenue with accelerated growth expected in 2027.

ResearchAndMarkets.com released a comprehensive market report on China's adult feeding tubes and formula market through 2033, providing revenue, volume, and pricing forecasts. The report analyzes two main segments (Adult Feeding Tubes and Adult Feeding Formula) and includes competitive landscape data with 2025 company share information for key market participants.

The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.

Johnson & Johnson's MedTech segment experienced mixed results in Q2 2026, with growth slowing due to weaker Cardiovascular sales and declining Abiomed procedures, though Shockwave showed strong double-digit growth. The company expects improvement in H2 2026 driven by Vision, Orthopedics, and Surgery segments, but faces ongoing headwinds from China's VBP program and competitive pressures.

Intuitive Surgical faces headwinds in China due to weak tenders, domestic competition, and pricing pressure, with only two systems placed. However, the company is diversifying growth through strong momentum in India following da Vinci 5 clearance and improved conditions in Japan with new reimbursement policies supporting 25 system placements. International da Vinci procedures grew 20% in Q2, with management maintaining its 2026 procedure growth outlook of 13.5-15.5%.